Table 2 Characteristics of patients treated with CDK4/6is plus ET.

From: Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

Treatment characteristic

CDK4/6is + ET, n = 2249

IDC, n = 1834 (81%)

ILC, n = 336 (15%)

Mixed, n = 79 (4%)

CDK4/6is, n (%)

 Palbociclib

1709 (93)

310 (92)

74 (94)

 Ribociclib

51 (3)

5 (2)

2 (3)

 Abemaciclib

74 (4)

21 (6)

3 (4)

Line of therapy, n (%)

 1L

1245 (68)

248 (74)

58 (73)

 2L+

589 (32)

88 (26)

21 (27)

ET backbone in 1L, n (%)

 Aromatase inhibitor

829 (67)

158 (64)

34 (59)

 Fulvestrant

416 (33)

90 (36)

24 (41)

  1. CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, mixed mixed invasive ductal and lobular carcinoma, 1L first line, 2L+ second line and beyond.
Back to article page